Mylan Inc (MYL) 44.78 $MYL
Watch for Mylan to Potentially Rebound After Falling 2.08% Yesterday
Comtex SmarTrend(R) - Fri Mar 04, 5:37PM CST
Mylan (NASDAQ:MYL) traded in a range yesterday that spanned from a low of $44.30 to a high of $46.02. Yesterday, the shares fell 2.1%, which took the trading range below the 3-day low of $44.87 on volume of 5.9 million shares. Often times after large one-day declines, short-term traders may play for some degree of mean reversion.
MYL: 44.78 (-0.95)
Mylan to Present at the Barclays Global Healthcare Conference
PR Newswire - Fri Mar 04, 9:30AM CST
Mylan N.V. (NASDAQ, TASE: MYL) today announced that the Company will present at the Barclays Global Healthcare Conference on Tuesday, March 15, 2016, in Miami. The presentation is scheduled to begin at 3:50 p.m. ET.
MYL: 44.78 (-0.95)
Mylan to Present at the Raymond James 37th Annual Institutional Investors Conference
PR Newswire - Fri Mar 04, 9:00AM CST
Mylan N.V. (NASDAQ, TASE: MYL) today announced that the Company will present at the Raymond James 37th Annual Institutional Investors Conference on Wednesday, March 9, 2016, in Orlando. The presentation is scheduled to begin at 10:25 a.m. ET.
MYL: 44.78 (-0.95)
10 Stocks Billionaire David Einhorn Loves for 2016
at The Street - Sun Feb 21, 3:48PM CST
David Einhorn is a man of many talents, including playing poker -- and watching where he stacks his chips investment-wise is a worthwhile endeavor, too.
CI: 138.94 (-1.49), DSW: 25.83 (-0.41), AGN: 288.67 (-0.95), TERP: 9.84 (+0.36), AGR: 38.53 (-0.05), MYL: 44.78 (-0.95), M: 44.58 (+0.49), EMC: 26.31 (-0.01), SNDK: 75.84 (+0.12), HUM: 183.25 (+0.03)
Tracking John Paulson's Paulson & Company Portfolio - Q4 2015 Update
John Vincent - at Seeking Alpha - Sat Feb 20, 1:39PM CST
SGYP: 3.47 (-0.01), PRGO: 126.61 (+0.19), CAM: 67.79 (-0.03), CHTR: 184.78 (+1.11), INTC: 30.63 (+0.05), PCP: 234.95 (+0.10), SLB: 74.83 (-0.02), CYBX: 69.95 (+0.86), HOT: 70.55 (+0.48), STAY: 14.82 (-0.27), CSC: 30.51 (-0.26), TMUS: 38.48 (-0.49), MNK: 62.15 (-1.44), WLL: 7.09 (+0.78), AKRX: 25.08 (-0.80), NCQ: 0.46 (+0.05), AU: 12.92 (-0.36), MYL: 44.78 (-0.95), MGM: 19.81 (-0.52), WWAV: 41.15 (+0.60), NG: 5.02 (-0.01), LIVN: 57.94 (+0.19), TEVA: 55.62 (+0.02), AIG: 52.30 (+0.03), BRK.B: 137.97 (+1.13), BRK.A: 207,945.00 (+1,945.00), OAS: 6.91 (+0.22), VRX: 61.31 (-3.58), VNDA: 7.92 (-0.21), ALTR: 53.96 (+0.03), CZR: 8.80 (-0.15), CVC: 33.28 (+0.03), CIE: 3.41 (+0.21), AGN: 288.67 (-0.95), CACQ: 5.75 (-0.15), SHPG: 160.39 (+0.20), TWC: 195.33 (+0.90), BXLT: 39.47 (+0.17), ENDP: 42.44 (-0.73), OUT: 21.56 (+0.06), BAC: 13.54 (+0.04), MAR: 68.98 (+0.30), GRFS: 15.22 (-0.27), HCA: 73.00 (+0.07), POST: 71.75 (-0.45), RDN: 11.94 (+0.16), LRCX: 74.33 (-0.54), BAX: 39.46 (+0.13), GLD: 120.54 (-0.19), RLGY: 34.27 (+0.38), CIT: 33.17 (+1.11), HMHC: 19.96 (+0.19), MTG: 7.55 (-0.02), CSRA: 25.82 (-0.30)
Momenta Posts Wider-than-Expected Loss in Q4, Shares Fall
Zacks Equity Research - Zacks Investment Research - Fri Feb 19, 12:25PM CST
Momenta Pharmaceuticals Inc. (MNTA) reported a loss of 43 cents per share in the fourth quarter of 2015, much wider than the Zacks Consensus Estimate of a loss of 10 cents per share.
MYL: 44.78 (-0.95), TEVA: 55.62 (+0.02), BXLT: 39.47 (+0.17), MNTA: 8.46 (-0.19)
FDA to review Mylan's ANDA for generic version of Glaxo's Advair Diskus
Seeking Alpha - at Seeking Alpha - Fri Feb 19, 11:50AM CST
MYL: 44.78 (-0.95), GSK: 39.14 (-0.04)
Mylan's ANDA for Generic Advair Diskus® Accepted for Filing by FDA
PR Newswire - Fri Feb 19, 10:36AM CST
Mylan N.V. (NASDAQ, TASE: MYL) today announced that its abbreviated new drug application (ANDA) for fluticasone propionate 100, 250, 500 mcg and salmeterol 50 mcg inhalation powder has been accepted for filing by the U.S. Food and Drug Administration (FDA). The FDA provided Mylan a GDUFA goal date of March 28, 2017. This product is the generic version of GlaxoSmithKline's Advair Diskus®, which is indicated for the treatment of asthma and the maintenance treatment of airflow obstruction and reducing exacerbations in patients with chronic obstructive pulmonary disease (COPD).
MYL: 44.78 (-0.95), GSK: 39.14 (-0.04)
Generic ETF in Focus as Biotech Lose Charm
Zacks Equity Research - ZACKS - Wed Feb 17, 6:59AM CST
With biotech sector caught in a nasty web of lingering headwinds, this generic ETF invites attention.
AGN: 288.67 (-0.95), JNJ: 106.50 (-0.15), GNRX: 24.10 (unch), AZN: 28.87 (+0.13), PFE: 29.71 (-0.18), XBI: 51.94 (+0.22), AMGN: 145.98 (+0.14), MYL: 44.78 (-0.95), IBB: 263.13 (-1.11), TEVA: 55.62 (+0.02), GSK: 39.14 (-0.04), NVS: 72.20 (-0.75)
Mylan to buy Sweden's Meda AB for $7.2 billion
AP - Wed Feb 10, 4:42PM CST
NEW YORK (AP) — Drugmaker Mylan says it will buy Meda AB of Sweden for $7.2 billion in cash and stock, and says the move will help it enter new markets.
ABT: 39.18 (+0.36), MYL: 44.78 (-0.95)
Mylan Full Year Adjusted Diluted EPS Up 21% to $4.30
PR Newswire - Wed Feb 10, 3:10PM CST
Mylan N.V. (NASDAQ, TASE: MYL) today announced its financial results for the quarter and year ended December 31, 2015.
MYL: 44.78 (-0.95)
CTI BioPharma's Myelofibrosis Drug on Full Clinical Hold
Zacks Equity Research - Zacks Investment Research - Wed Feb 10, 3:04PM CST
CTI BioPharma Corp. (CTIC) announced that the FDA has placed the company's Investigational New Drug (IND) application for pacritinib on a full clinical hold.
GILD: 87.21 (-0.62), MYL: 44.78 (-0.95), CTIC: 0.59 (-0.01), PCRX: 54.25 (unch)
Mylan to Acquire Meda
PR Newswire Europe - Wed Feb 10, 3:03PM CST
The Offer is not being made, and this press release may not be distributed, directly or indirectly, in or into, nor will any tender of shares be accepted from or on behalf of holders in, any jurisdiction in which the making of the Offer, the distribution of this press release or the acceptance of any tender of shares would contravene applicable laws or regulations or require further offer documents, filings or other measures in addition to those required under Swedish law, Dutch law and U.S. law.
MYL: 44.78 (-0.95)
Mylan (MYL) to Report Q4 Earnings: What's in the Cards?
Zacks Equity Research - Zacks Investment Research - Mon Feb 08, 9:30AM CST
Mylan (MYL) is scheduled to report fourth-quarter 2015 earnings results on Feb 10, after the opening bell.
CYTK: 6.27 (-0.23), SHPG: 160.39 (+0.20), MYL: 44.78 (-0.95), ACOR: 36.00 (+0.53)
The Zacks Analyst Blog Highlights: Gilead Sciences, Mylan, United Therapeutics and INSYS Therapeutics
Zacks Equity Research - Zacks Investment Research - Wed Feb 03, 8:30AM CST
The Zacks Analyst Blog Highlights: Gilead Sciences, Mylan, United Therapeutics and INSYS Therapeutics
INSY: 17.96 (-0.26), GILD: 87.21 (-0.62), UTHR: 127.64 (+1.64), MYL: 44.78 (-0.95)
Watch for Mylan to Potentially Rebound After Falling 2.08% Yesterday
Comtex SmarTrend(R) - Fri Mar 04, 5:37PM CST
Mylan (NASDAQ:MYL) traded in a range yesterday that spanned from a low of $44.30 to a high of $46.02. Yesterday, the shares fell 2.1%, which took the trading range below the 3-day low of $44.87 on volume of 5.9 million shares. Often times after large one-day declines, short-term traders may play for some degree of mean reversion.
MYL: 44.78 (-0.95)
Mylan to Present at the Barclays Global Healthcare Conference
PR Newswire - Fri Mar 04, 9:30AM CST
Mylan N.V. (NASDAQ, TASE: MYL) today announced that the Company will present at the Barclays Global Healthcare Conference on Tuesday, March 15, 2016, in Miami. The presentation is scheduled to begin at 3:50 p.m. ET.
MYL: 44.78 (-0.95)
Mylan to Present at the Raymond James 37th Annual Institutional Investors Conference
PR Newswire - Fri Mar 04, 9:00AM CST
Mylan N.V. (NASDAQ, TASE: MYL) today announced that the Company will present at the Raymond James 37th Annual Institutional Investors Conference on Wednesday, March 9, 2016, in Orlando. The presentation is scheduled to begin at 10:25 a.m. ET.
MYL: 44.78 (-0.95)
10 Stocks Billionaire David Einhorn Loves for 2016
at The Street - Sun Feb 21, 3:48PM CST
David Einhorn is a man of many talents, including playing poker -- and watching where he stacks his chips investment-wise is a worthwhile endeavor, too.
CI: 138.94 (-1.49), DSW: 25.83 (-0.41), AGN: 288.67 (-0.95), TERP: 9.84 (+0.36), AGR: 38.53 (-0.05), MYL: 44.78 (-0.95), M: 44.58 (+0.49), EMC: 26.31 (-0.01), SNDK: 75.84 (+0.12), HUM: 183.25 (+0.03)
Tracking John Paulson's Paulson & Company Portfolio - Q4 2015 Update
John Vincent - at Seeking Alpha - Sat Feb 20, 1:39PM CST
SGYP: 3.47 (-0.01), PRGO: 126.61 (+0.19), CAM: 67.79 (-0.03), CHTR: 184.78 (+1.11), INTC: 30.63 (+0.05), PCP: 234.95 (+0.10), SLB: 74.83 (-0.02), CYBX: 69.95 (+0.86), HOT: 70.55 (+0.48), STAY: 14.82 (-0.27), CSC: 30.51 (-0.26), TMUS: 38.48 (-0.49), MNK: 62.15 (-1.44), WLL: 7.09 (+0.78), AKRX: 25.08 (-0.80), NCQ: 0.46 (+0.05), AU: 12.92 (-0.36), MYL: 44.78 (-0.95), MGM: 19.81 (-0.52), WWAV: 41.15 (+0.60), NG: 5.02 (-0.01), LIVN: 57.94 (+0.19), TEVA: 55.62 (+0.02), AIG: 52.30 (+0.03), BRK.B: 137.97 (+1.13), BRK.A: 207,945.00 (+1,945.00), OAS: 6.91 (+0.22), VRX: 61.31 (-3.58), VNDA: 7.92 (-0.21), ALTR: 53.96 (+0.03), CZR: 8.80 (-0.15), CVC: 33.28 (+0.03), CIE: 3.41 (+0.21), AGN: 288.67 (-0.95), CACQ: 5.75 (-0.15), SHPG: 160.39 (+0.20), TWC: 195.33 (+0.90), BXLT: 39.47 (+0.17), ENDP: 42.44 (-0.73), OUT: 21.56 (+0.06), BAC: 13.54 (+0.04), MAR: 68.98 (+0.30), GRFS: 15.22 (-0.27), HCA: 73.00 (+0.07), POST: 71.75 (-0.45), RDN: 11.94 (+0.16), LRCX: 74.33 (-0.54), BAX: 39.46 (+0.13), GLD: 120.54 (-0.19), RLGY: 34.27 (+0.38), CIT: 33.17 (+1.11), HMHC: 19.96 (+0.19), MTG: 7.55 (-0.02), CSRA: 25.82 (-0.30)
Momenta Posts Wider-than-Expected Loss in Q4, Shares Fall
Zacks Equity Research - Zacks Investment Research - Fri Feb 19, 12:25PM CST
Momenta Pharmaceuticals Inc. (MNTA) reported a loss of 43 cents per share in the fourth quarter of 2015, much wider than the Zacks Consensus Estimate of a loss of 10 cents per share.
MYL: 44.78 (-0.95), TEVA: 55.62 (+0.02), BXLT: 39.47 (+0.17), MNTA: 8.46 (-0.19)
FDA to review Mylan's ANDA for generic version of Glaxo's Advair Diskus
Seeking Alpha - at Seeking Alpha - Fri Feb 19, 11:50AM CST
MYL: 44.78 (-0.95), GSK: 39.14 (-0.04)
Mylan's ANDA for Generic Advair Diskus® Accepted for Filing by FDA
PR Newswire - Fri Feb 19, 10:36AM CST
Mylan N.V. (NASDAQ, TASE: MYL) today announced that its abbreviated new drug application (ANDA) for fluticasone propionate 100, 250, 500 mcg and salmeterol 50 mcg inhalation powder has been accepted for filing by the U.S. Food and Drug Administration (FDA). The FDA provided Mylan a GDUFA goal date of March 28, 2017. This product is the generic version of GlaxoSmithKline's Advair Diskus®, which is indicated for the treatment of asthma and the maintenance treatment of airflow obstruction and reducing exacerbations in patients with chronic obstructive pulmonary disease (COPD).
MYL: 44.78 (-0.95), GSK: 39.14 (-0.04)
Generic ETF in Focus as Biotech Lose Charm
Zacks Equity Research - ZACKS - Wed Feb 17, 6:59AM CST
With biotech sector caught in a nasty web of lingering headwinds, this generic ETF invites attention.
AGN: 288.67 (-0.95), JNJ: 106.50 (-0.15), GNRX: 24.10 (unch), AZN: 28.87 (+0.13), PFE: 29.71 (-0.18), XBI: 51.94 (+0.22), AMGN: 145.98 (+0.14), MYL: 44.78 (-0.95), IBB: 263.13 (-1.11), TEVA: 55.62 (+0.02), GSK: 39.14 (-0.04), NVS: 72.20 (-0.75)
Mylan to buy Sweden's Meda AB for $7.2 billion
AP - Wed Feb 10, 4:42PM CST
NEW YORK (AP) — Drugmaker Mylan says it will buy Meda AB of Sweden for $7.2 billion in cash and stock, and says the move will help it enter new markets.
ABT: 39.18 (+0.36), MYL: 44.78 (-0.95)
Mylan Full Year Adjusted Diluted EPS Up 21% to $4.30
PR Newswire - Wed Feb 10, 3:10PM CST
Mylan N.V. (NASDAQ, TASE: MYL) today announced its financial results for the quarter and year ended December 31, 2015.
MYL: 44.78 (-0.95)
CTI BioPharma's Myelofibrosis Drug on Full Clinical Hold
Zacks Equity Research - Zacks Investment Research - Wed Feb 10, 3:04PM CST
CTI BioPharma Corp. (CTIC) announced that the FDA has placed the company's Investigational New Drug (IND) application for pacritinib on a full clinical hold.
GILD: 87.21 (-0.62), MYL: 44.78 (-0.95), CTIC: 0.59 (-0.01), PCRX: 54.25 (unch)
Mylan to Acquire Meda
PR Newswire Europe - Wed Feb 10, 3:03PM CST
The Offer is not being made, and this press release may not be distributed, directly or indirectly, in or into, nor will any tender of shares be accepted from or on behalf of holders in, any jurisdiction in which the making of the Offer, the distribution of this press release or the acceptance of any tender of shares would contravene applicable laws or regulations or require further offer documents, filings or other measures in addition to those required under Swedish law, Dutch law and U.S. law.
MYL: 44.78 (-0.95)
Mylan (MYL) to Report Q4 Earnings: What's in the Cards?
Zacks Equity Research - Zacks Investment Research - Mon Feb 08, 9:30AM CST
Mylan (MYL) is scheduled to report fourth-quarter 2015 earnings results on Feb 10, after the opening bell.
CYTK: 6.27 (-0.23), SHPG: 160.39 (+0.20), MYL: 44.78 (-0.95), ACOR: 36.00 (+0.53)
The Zacks Analyst Blog Highlights: Gilead Sciences, Mylan, United Therapeutics and INSYS Therapeutics
Zacks Equity Research - Zacks Investment Research - Wed Feb 03, 8:30AM CST
The Zacks Analyst Blog Highlights: Gilead Sciences, Mylan, United Therapeutics and INSYS Therapeutics
INSY: 17.96 (-0.26), GILD: 87.21 (-0.62), UTHR: 127.64 (+1.64), MYL: 44.78 (-0.95)
